￥ 人民币 $ USD € 欧元
简体中文 English 繁体中文
Menu

News

Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Did Jisandai (Bingtonsha) relapse after three months of treatment? Coping strategies and precautions

2026-02-01 22:25:32

Check Details
Jisandai (Bingtonsha): an efficient choice for hepatitis C treatment?

2026-02-01 22:25:32

Check Details
What effect does Jisandai (Bingtonsha) have on renal function in treating hepatitis C?

2026-02-01 22:25:32

Check Details
How long is the standard course of treatment for hepatitis C with Jisandai (Bingtonsha)?

2026-02-01 22:25:32

Check Details
Is there any risk of hepatotoxicity with Jisandai (Bingtonsha) in treating hepatitis C?

2026-02-01 22:25:32

Check Details
Possible adverse reactions and precautions of Jisandai (Bingtonsha) in the treatment of hepatitis C

2026-02-01 22:25:32

Check Details
Comprehensive comparative analysis of domestic and imported drugs of Jisandai (Bingtonsha)

2026-02-01 22:25:32

Check Details
How effective is Jisandai (Bingtonsha) in treating hepatitis C? In-depth analysis

2026-02-01 22:25:32

Check Details
Lorlatinib/lorlatinib: the latest progress and clinical application of third-generation ALK inhibitors

2026-02-01 22:25:32

Check Details
Beyond lorlatinib/lorlatinib: exploring the prospects of new fourth-generation ALK inhibitors

2026-02-01 22:25:32

Check Details
Lorlatinib/lorlatinib drug related specifications

2026-02-01 22:25:32

Check Details
Is lorlatinib/lorlatinib a domestic or imported drug?

2026-02-01 22:25:32

Check Details
Category
相关知识